Company intelligence / Profile preview
MedDay Pharmaceuticals
Paris, Île-de-France, Francemedday-pharma.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
MedDay’s lead candidate MD1003—a high-dose biotin formulation—has completed pivotal Phase 2b/3 studies in progressive multiple sclerosis with proof-of-concept showing up to 90% of subjects exhibiting clinical improvement. Additional programs are at earlier stages targeting rare neurological and psychiatric diseases. The company leverages its proprietary SPECMET platform for drug discovery focused on brain metabolism.
- Therapeutic areas
- PsychiatryRare DiseasesNeurology
- Modalities
- small molecules (notably high-dose pharmaceutical-grade biotin)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
European Leukodystrophy Association funds the AMN trial; no major pharma partnerships disclosed
Beyond the preview
Go deeper on MedDay Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedDay Pharmaceuticals.